Genmab A/S

Genmab is a biotechnology company specializing in the creation and development of differentiated human antibody therapeutics focused on the treatment of cancer. Co.'s product pipeline includes one marketed product, Arzerra, daratumumab in late stage clinical development, four antibodies in clinical development, and over 20 in-house and partnered pre-clinical programs. Co.'s Arzerra (ofatumumab) is a human monoclonal antibody which targets an epitope on the CD20 molecule. Co.'s proprietary technologies include the DuoBody technology, which creates antibodies that can target two molecules at once, and the HexaBody technology, which allows for the creation of more potent antibodies.
  • TickerGEN
  • ISINDK0010272202
  • ExchangeNasdaq Nordic Copenhagen
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark

Analysts

Expert Corporate Governance Service (ECGS)

Genmab, March 29 2019

In general, Genmab is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEM 2, it is proposed to approve the Company's financial statements and to discharge the board of directors and executive management from liability for the FY 2018. Although ECGS has no concerns over the annual accounts it does not approve of the discharge requested. ECGS accordingly recommends to vote OPPOSE. Under ITEM 4a, it is proposed to re-appoint Mr. Mats Pettersson as Chairman of the board of directors. Although he is considered independent...

Karen Andersen

Morningstar | Genmab's Earnings Beat Expectations With Strong Darzalex Sales; Higher Royalty Rate for 2019

No-moat Genmab reported a strong close to fiscal 2018, finishing with over DKK 3 billion in full-year sales, up nearly 28% from the prior year. The full-year results were slightly above our and analyst expectations but within company guidance. The company's top-line growth was largely driven by quick uptake of Darzalex in front-line multiple myeloma (partnered with Johnson & Johnson). Johnson & Johnson reported full-year Darzalex sales of over $2 billion, meaning that the drug broke through a couple royalty tiers in the fourth quarter: 16% for $1.5 billion in sales and 18% for $2 billion in sa...

Karen Andersen

Morningstar | We're Expecting Robust Darzalex Sales, but Genmab Needs Diversification to Earn a Moat

Genmab uses its expertise in antibody technology to develop cancer drugs, including the highly promising first-in-class multiple myeloma treatment Darzalex (daratumumab). Its DuoBody and HexaBody technology platforms have attracted a number of biopharma partners. Darzalex is currently on the market for fourth-line relapsed/refractory patients, second-line treatment (in combination with dexamethasone and Velcade/Revlimid), and was recently approved in the U.S. for front-line therapy (with Velcade, melphalan, and prednisone, or VMP). Most significantly, the drug has the potential to be a corners...

Karen Andersen

Genmab's Earnings Beat Expectations With Strong Darzalex Sales; Higher Royalty Rate for 2019

No-moat Genmab reported a strong close to fiscal 2018, finishing with over DKK 3 billion in full-year sales, up nearly 28% from the prior year. The full-year results were slightly above our and analyst expectations but within company guidance. The company's top-line growth was largely driven by quick uptake of Darzalex in front-line multiple myeloma (partnered with Johnson & Johnson). Johnson & Johnson reported full-year Darzalex sales of over $2 billion, meaning that the drug broke thro...

Karen Andersen

We're Expecting Robust Darzalex Sales, but Genmab Needs Diversification to Earn a Moat

No-moat Genmab's third-quarter results were mostly in line with our expectations, posting DKK 599 million in total revenue, an 85% increase from last year due to strong uptake of Darzalex globally. Operating expenses have increased from last year as well, with third-quarter expenses reaching DKK 398 million, up 50% from last year. The firm maintained full-year guidance, and after some minor near-term adjustments, we are maintaining our fair value estimate of DKK 1160 per share. On Aug. 31, Genm...

Hugo Solvet

GENMAB: On track for a better than expected year in 2019 | BUY | DKK1300 vs. DKK1200

GENMAB - BUY | DKK1300 vs. DKK1200 (+29%) On track for a better than expected year in 2019 While 2018 was in line with the consensus … 2019 top-line guidance is way above analysts’ expectations Filing of MAIA and CASSIOPEIA should support Darzalex growth Other catalysts should bring value this year Buy reiterated and FV updated to DKK1300

1 director bought

A director at Genmab AS bought 1,200 shares at 912.620DKK and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Eivind Sars Veddeng ...
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Alexander Aukner ...
  • Joachim Gunell
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Nicolay Dyvik
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Eivind Sars Veddeng ...
  • Håkon Astrup
  • Jon Masdal
  • Martin Arnell
  • Mattias Montgomery
  • Nicolas McBeath
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

GENMAB A/S sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of GENMAB A/S (DK), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date November 9, 2018, the closing price was DKK 992.40 and its potential was estimated at DKK 1,164.63.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Hugo Solvet

GENMAB: ASH 2018 confirms once again Darzalex’s domination | BUY - TOP PICKS | DKK1262(

GENMAB - BUY - TOP PICKS | DKK1262(+26%) ASH 2018 confirms once again Darzalex’s domination Darzalex: the rituximab of the myeloma world? DARA is so good, we need to bring out new endpoints Can it still be challenged by competitors? “It is only the beginning” according to CEO

Eric Le Berrigaud ...
  • Gary Waanders
  • Hugo Solvet
  • Jean-Jacques Le Fur

Healthcare: Five picks in healthcare in Q4 with Fresenius, Galapagos, Genmab, Novartis and Sanofi

Healthcare Five picks in healthcare in Q4 with Fresenius, Galapagos, Genmab, Novartis and Sanofi

GlobalData Healthcare Department

Genmab AS (GEN) - Medical Equipment - Deals and Alliances Profile

Summary Genmab A/S (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company's marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are used to treat chronic lymphocytic leukemia and to treat patients with multiple myeloma respectively. Genmab’s products are based on three next generation antibody technologies, namely, HexaBody, DuoBody, and antibody drug conjugate (ADC) technologies. Genmab partnered with various pharmaceutical and biotechnology companies for the co-development and commercialization of ...

Expert Corporate Governance Service (ECGS)

Genmab, March 29 2019

In general, Genmab is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEM 2, it is proposed to approve the Company's financial statements and to discharge the board of directors and executive management from liability for the FY 2018. Although ECGS has no concerns over the annual accounts it does not approve of the discharge requested. ECGS accordingly recommends to vote OPPOSE. Under ITEM 4a, it is proposed to re-appoint Mr. Mats Pettersson as Chairman of the board of directors. Although he is considered independent...

Genmab – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch